Kjersti Bakken, Agnès Fournier, Eiliv Lund, Marit Waaseth, Vanessa Dumeaux, Françoise Clavel-Chapelon, Alban Fabre, Bertrand Hémon, Sabina Rinaldi, Véronique Chajes, Nadia Slimani, Naomi E Allen, Gillian K Reeves, Sheila Bingham, Kay-Tee Khaw, Anja Olsen, Anne Tjønneland, Laudina Rodriguez, Maria-José Sánchez, Pilar Amiano Etxezarreta, Eva Ardanaz, Maria-José Tormo, Petra H Peeters, Carla H van Gils, Annika Steffen, Mandy Schulz, Jenny Chang-Claude, Rudolf Kaaks, Rosario Tumino, Valentina Gallo, Teresa Norat, Elio Riboli, Salvatore Panico, Giovanna Masala, Carlos A González, Franco Berrino
Menopausal hormone therapy (MHT) is characterized by use of different constituents, regimens and routes of administration. We investigated the association between the use of different types of MHT and breast cancer risk in the EPIC cohort study. The analysis is based on data from 133,744 postmenopausal women. Approximately 133,744 postmenopausal women contributed to this analysis. Information on MHT was derived from country-specific self-administered questionnaires with a single baseline assessment. Incident breast cancers were identified through population cancer registries or by active follow-up (mean: 8...
January 1, 2011: International Journal of Cancer. Journal International du Cancer